Heart Failure Model

Model Description

Heart failure is the end-stage of various cardiovascular diseases. HuaTeng Biotechnology offers a suite of HF models that replicate diverse clinical phenotypes, including HFrEF (induced by MI or Doxorubicin) and HFpEF (induced by hypertension/TAC or metabolic stress), allowing for targeted therapeutic evaluation.

Applications

• Evaluation of novel inotropic agents and diuretics.

• Validation of heart failure medical devices (e.g., VADs, CCM).

• Research on cardiac remodeling, fibrosis, and gene therapies.

• Safety and efficacy testing for regenerative medicine (stem cells).

Modeling Methods

HuaTeng Biotechnology provides multiple induction pathways:

• Surgical Ligation (MI): Permanent ligation of the LAD to induce ischemic cardiomyopathy (HFrEF).

• Pressure Overload (TAC): Transverse Aortic Constriction to induce hypertrophic HF.

• Pharmacological Induction: Chronic Doxorubicin dosing for dilated cardiomyopathy.

• Volume Overload: Aortocaval fistula (ACF) models.

Testing Items

• Cardiac Imaging: High-end Echocardiography (EF, FS, E/A ratio), Cardiac MRI.

• Hemodynamics: Invasive Pressure-Volume (P-V) loops (Gold standard for contractility).

• Biomarkers: Plasma NT-proBNP, ANP, Troponin levels.

• Morphology: Heart weight/Body weight ratio, Lung water content (Edema assessment).

• Histology: Wheat Germ Agglutinin (WGA) staining for myocyte hypertrophy, Masson's for fibrosis.

Data